Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes - Wikidata - awgldk - TriplyDB

Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes

Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes

http://www.wikidata.org/entity/Q31150044

about

Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future.Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation.An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.Markov model for characterizing neuropsychologic impairment and Monte Carlo simulation for optimizing efavirenz therapy.CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.Role of Cytochrome P450 2B6 Pharmacogenomics in Determining Efavirenz-Mediated Central Nervous System Toxicity, Treatment Outcomes, and Dosage Adjustments in Patients with Human Immunodeficiency Virus Infection.Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.Outcome of the second Medicines Utilisation Research in Africa Group meeting to promote sustainable and appropriate medicine use in Africa.Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.Human cytochrome P450 2B6 genetic variability in Botswana: a case of haplotype diversity and convergent phenotypes.Incidence of neuropsychiatric side effects of efavirenz in HIV-positive treatment-naïve patients in public-sector clinics in the Eastern Cape.Is there a role of pharmacogenomics in Africa.Effects of Khat (Catha edulis) use on catalytic activities of major drug-metabolizing cytochrome P450 enzymes and implication of pharmacogenetic variations Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype

P2860

Q28069383-DDD52D9F-88BD-44C2-AAB7-183B3685C387 Q35023687-1983BDB3-DE95-4F6E-9AFE-F58982B1FF65 Q35910664-0D2C9820-04FB-42A1-8BF2-B0B67C8A69A7 Q36437792-B5B4A635-7414-4C9D-A617-DAD1897E94F7 Q36554279-D59096E7-BF48-4C2D-BD43-2350227EB890 Q36966640-62732153-D045-4D27-B2F5-D9B9926428D3 Q38414396-A2BF70B2-7E70-4A0A-BCEB-EEE31CB5AC51 Q38755666-83265284-9E66-4D37-ADF1-96F7C4AF67D1 Q38855121-BC274FB2-8152-4A9A-9B1D-AF0C8B916E4D Q38859179-8F95DBFA-AD06-487A-B152-D40EE14D101E Q38861140-EE0ADF38-4B83-4CC9-B1F4-8940D20F8F26 Q38990321-BDD404C5-FFAF-4954-B864-891E1C3257CF Q39039468-27786744-99D9-4CDD-80BC-58837F41DF01 Q40050910-C9CBB61B-5AE5-44E8-8C46-22A644495D9E Q40563423-30E6C458-90B8-439B-84EA-040DFB900E34 Q40792327-6575C3FE-E381-45FF-8BC5-1486A3350909 Q46600089-7A65ACC8-63DB-4C0D-BCE2-1330203B80C7 Q51365463-59A175BF-6C87-4F9A-B6F1-830A42E92211 Q53759304-0376A49F-8EB6-4220-A29C-579F80C7A157 Q54964575-8B5A0CC8-C8FC-480B-92A2-64E17BF396DF Q58003058-51E9031E-ABB6-4BA8-A19E-E3613BAB8B00 Q58612379-04C7000C-E48F-4DE0-9A6C-555642457D38

P2860

Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes

http://www.wikidata.org/entity/Q31150044

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Pharmacogenetic-based efaviren ...... the different CYP2B6 genotypes

@ast

Pharmacogenetic-based efaviren ...... the different CYP2B6 genotypes

@en

type

label

Pharmacogenetic-based efaviren ...... the different CYP2B6 genotypes

@ast

Pharmacogenetic-based efaviren ...... the different CYP2B6 genotypes

@en

prefLabel

Pharmacogenetic-based efaviren ...... the different CYP2B6 genotypes

@ast

Pharmacogenetic-based efaviren ...... the different CYP2B6 genotypes

@en

P1433

Q31150044-DBEC0B68-FE2B-4BB0-9260-2298CAA517F5

P1476

Q31150044-30019CB3-338C-4879-8CB2-1652BA034A9F

P2093

Q31150044-0878F57E-1FE9-4BA6-9714-3EA40B5A45F2

Q31150044-3461B29A-0BEB-41C5-858D-14CF010B6B4B

Q31150044-5963A002-053D-4B32-98A8-962942269773

Q31150044-76E1EF44-2A6F-4558-B127-574403FFC66D

Q31150044-DAA4438C-DD1C-42AF-B8BA-3AF4E16B0E1B

Q31150044-FC6BBE59-4624-4E21-9E64-989F51A8B42F

P2860

Q31150044-1D381383-4D60-4E1A-8306-8197D039847D

Q31150044-2357B31D-DE4F-4196-B84F-1464EE816614

Q31150044-259FFD1B-A22C-40CD-9034-C513ECBFA484

Q31150044-2BC25790-0CDB-49FA-ADBE-E995D2A59E88

Q31150044-381540DC-5791-471F-B6B8-C16A843BBF93

Q31150044-5CF30673-C74C-42CB-8801-58454C3EB07C

Q31150044-5FDF8C4A-A526-4781-8AA8-826955C018DF

Q31150044-6101E93E-ABE6-4558-AC94-71182169343E

Q31150044-66868D8E-7E36-41FC-BB6D-4A459835C025

Q31150044-6F886D43-9D7E-477D-AD2D-F808407B1883

P304

Q31150044-A9531D35-BDD9-489F-9079-9DFFDED6447D

P31

Q31150044-D2C088E2-4493-4B0B-B1BF-0EE6D0E30DB4

P356

Q31150044-14ADDC34-869E-42E3-BDA9-872AE9AD46A5

P407

Q31150044-BB41060B-FD94-49F1-9258-35590B4E489D

P433

Q31150044-DB027148-7DC2-44B7-9658-49BCBA04086F

P478

Q31150044-D75EF5F0-069D-40FE-83A7-C11A0902B2DB

P50

Q31150044-702E7C0A-F0FB-475E-A7CA-D9FC2BBD6C44

Q31150044-8E48CE01-D8BE-40B5-951B-CFED38A07CE7

Q31150044-94D9B255-E501-480B-81B1-18BB7F7FE00D

Q31150044-AB4FF627-4019-414F-96AE-E370E9D6C003

P577

Q31150044-BF1EE3DD-667F-427D-A400-AB610BE6C9B6

P5875

Q31150044-B2E6176F-441F-450F-A453-40DAE859D2D4

P698

Q31150044-CCF12C8E-284A-42FF-8ADB-2150838BA071

P932

Q31150044-FCB3B875-A730-4E9A-A2A5-55807399B192

P356

JOURNAL.PONE.0086919

P1433

P1476

Pharmacogenetic-based efaviren ...... the different CYP2B6 genotypes

@en

P2093

Colin Ross

http://www.w3.org/2001/XMLSchema#string

Jackson K Mukonzo

http://www.w3.org/2001/XMLSchema#string

Jasper Ogwal-Okeng

http://www.w3.org/2001/XMLSchema#string

Joel S Owen

http://www.w3.org/2001/XMLSchema#string

Ronald B Kuteesa

http://www.w3.org/2001/XMLSchema#string

Sarah Nanzigu

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study

Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda.

Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort.

Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.

Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations

Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism

Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.

P304

e86919

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0086919

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Lars L. Gustafsson

Nelson Sewankambo

P577

2014-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260108756

http://www.w3.org/2001/XMLSchema#string

P698

24497997

http://www.w3.org/2001/XMLSchema#string

P932

3909010

http://www.w3.org/2001/XMLSchema#string